DIAGNOS Announces its New Mission in Healthcare after its Divestiture from the Mining Industry
BROSSARD, QUEBEC--(Marketwired - May 31, 2017) - Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX
VENTURE:ADK), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces its new
mission in healthcare.
Further to the news release dated May 17th, 2017, the Corporation has received a certificate for 8,000,000 common
shares of Majescor Resources Inc. pursuant to the sale of the assets from its mining division initially announced on March
15th, 2017. From now on, the Corporation's will solely focus on Healthcare with a mission of early detection of
critical health issues through the use of its Artificial Intelligence ("AI") tool CARA (Computer Assisted Retina Analysis).
AI gets real!
AI in healthcare aims to improve patient outcomes by assisting healthcare practitioners in using medical knowledge
dramatically. The AI market for healthcare applications is expected to achieve rapid adoption globally, with a compound annual
growth rate of 42 percent until 2021. By 2020, chronic conditions such as cancer and diabetes are expected to be diagnosed in
minutes using cognitive systems. By 2025, AI systems are expected to be implemented in 90 percent of the US and 60 percent of the
global hospitals and insurance companies (source JP Morgan).
Today DIAGNOS helps take care of more than 135,000 patients. We are using AI in more than 15 countries to help detect
anomalies in retina due to diabetic retinopathy. We are making a difference today and we are preventing blindness. DIAGNOS CARA
system combines the latest in advanced retinal imaging with clinical interpretation of the images. The painless, non-invasive
procedure takes minutes to complete, and gives a visual representation of the states of one's diabetes.
As per DIAGNOS's President, Andre Larente, "Early diagnosis allows doctor to prescribe treatments earlier. With our CARA
solution, we intend to diminish the highly repetitive work in screening a large group of patients and empower doctor to spend
more quality time in delivering care."
About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission of early detection of critical health issues
through the use of its Artificial Intelligence ("AI") tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care
(POC). CARA's Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to
read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus
cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been
approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and in
Mexico.
Visit our new website at: http://www.diagnos.ca/.
This document contains forward-looking information. There can be no assurance that forward-looking information will prove
to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS
disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new
information, future events or otherwise. The forward-looking information contained in this news release are expressly qualified
by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.